ClinicalTrials.gg
RecruitingNCT05181137Updated Sep 5, 2023

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of SHR0302 and Placebo in Ulcerative Colitis, sponsored by Reistone Biopharma Company Limited. Recruiting at 113 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 183 studies in Colitis, Ulcerative with a site in China — 72 open to participants now, 95 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Planned enrollment
28th of 135
368 · median 120
Started
2021
with 12 others
Phase 3
32 of 183
9 open now
Primary completion
2024-10
later than 5 of 94 live
Registered
67th of 183
by date

Among the 183 studies in Colitis, Ulcerative with a site in China, this one is the 28th largest by planned enrollment of the 135 interventional ones that give a count, is one of 13 that started in 2021, is one of 32 in phase 3, reaches primary completion later than 5 of the 94 other live ones, and was the 67th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

72 of the 183 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.

Read the detailed description

This study consists of a screening period followed by a placebo-controlled Part 1 phase and then a placebo-controlled Part 2 phase. An open label Part 3 phase is open to subjects who: complete the Part 2, are considered non-responders following the Part 1, or have disease worsening during Part 2.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for Part 1

  1. Male or female subjects must be at least at ≥18 and ≤75 years of age
  2. Subject has at least a three-month history of Ulcerative Colitis diagnosis at baseline.
  3. Subject has active Ulcerative Colitis with a 9-point modified Mayo score of ≥ 5 at baseline, with an endoscopic subscore of ≥ 2
  4. Subject is deemed by the physician as having inadequate response, loss of response or intolerance to at least one conventional treatment (oral 5-ASA, or ), or was previously exposed to anti-TNF therapy (e.g., infliximab, adalimumab) or other biological treatment (e.g., vedolizumab) having

Discontinued the treatment for:

  • Infliximab: a minimum of 8 weeks prior to baseline.
  • Adalimumab: a minimum of 10 weeks prior to baseline.
  • Ustekinumab: a minimum of 14 weeks prior to baseline.
  • Vedolizumab: a minimum of 17 weeks prior to baseline.

Inclusion Criteria for Part 2 1. Subject has completed Part 1 and achieved clinical response at week 8

Inclusion Criteria for Part 3

  1. Subject has completed the 8-week Part 1 and was classified as not meeting clinical response criteria. OR Subject has discontinued treatment early in the Maintenance phase due to disease worsening OR Subject has completed the Maintenance phase.

Study Exclusion Criteria for Part 1

Exclusion Criteria:

  1. Subject has a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn'sDisease.
  2. Subject with Ulcerative Colitis, which is confined to a proctitis (distal 15 cm or less).
  3. Treatment naïve subject diagnosed with Ulcerative Colitis (without previous exposure to any of the following therapies for UC treatment: oral 5-ASA, corticosteroids, immunosuppressants, or biological treatments).
  4. Subject is displaying clinical signs of ischemic colitis, fulminant colitis or toxic megacolon.
  5. Subject had previous surgery as a treatment for Ulcerative Colitis or likely to require surgery during the study period.
  6. Subject has evidence of pathogenic bowel infection. Subjects had Clostridium difficile or other intestinal infection within 30 days of screening endoscopy or test positive at screening for C.difficile toxin or other intestinal pathogens.
  7. Subject currently has or has a history of active tuberculosis (TB) or latent TB infection.
  8. Subject is receiving any of the following therapies:

    • Azathioprine/6-mercaptopurine, methotrexate, thalidomide within 7 days prior to baseline.
    • Cyclosporine, mycophenolate, tacrolimus within 4 weeks prior to baseline.
    • Interferon therapy within 8 weeks prior to baseline.
    • Intravenous corticosteroids or rectally administered formulation of corticosteroids or 5- ASA within 2 weeks prior to baseline.
  9. Subject had any prior treatment with lymphocyte-depleting agents/therapies (such as CamPath® [alemtuzumab], alkylating agents [e.g., cyclophosphamide or chlorambucil], total lymphoid irradiation, etc.). Subjects who have received rituximab or other selective B lymphocyte depleting agents are eligible if they have not received such therapy for at least 1 year prior to baseline.
  10. Subject has previously received JAK inhibitors, such as tofacitinib, baricitinib, upadacitinib, filgotinib.
  11. Subject with evidence of laboratory abnormalities which may affect subject safety or interpretation of study results at screening
  12. Subject has a screening 12-lead that demonstrates clinically relevant abnormalities
  13. Subject currently has or had:

    • A clinically significant infection within 1 month of baseline (e.g., those requiring hospitalization or parenteral antimicrobial therapy or have opportunistic infections).
    • A history of more than one episode of herpes zoster, or disseminated zoster (single episode).
    • Any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
    • Any infection requiring antimicrobial therapy within 2 weeks of screening.
  14. Subject has current immunization with any or history of immunization with any live virus vaccine within 8 weeks of baseline.
  15. Subject with a first-degree relative with a hereditary immunodeficiency.
  16. Subject with a history of any lymphoproliferative disorder (such as EBV-related lymphoproliferative disorder, as reported in some subjects on other immunosuppressive drugs), history of lymphoma, leukemia, multiple myeloma, or signs and symptoms that are suggestive of current lymphatic disease.
  17. Subject has any condition possibly affecting oral drug absorption e.g., gastrectomy, or clinically significant diabetic gastroenteropathy, or certain types of bariatric surgery such as gastric bypass. (Procedures such as gastric banding, gastric balloon that simply divide stomach into separate chambers, are NOT exclusionary.) Subject has undergone significant trauma or major surgery within 4 weeks of baseline.
  18. Women who are pregnant or lactating, or planning pregnancy while enrolled in the study. Male who plan to donate sperm during the study and within 30 days after the last dose of study drug.
  19. Subject who has a history of alcohol or drug abuse with less than 6 months of abstinence prior to baseline that in the opinion of the investigator will preclude participation in the study.
  20. Subject with or with a history of malignancies with exception of adequately treated or excised non- basal cell or squamous cell cancer of the skin.
  21. Subject infected with (HIV) or or C viruses.
  22. Subject has received any drug or device within 3 months, or 5 half-lives (if known) prior to baseline.
  23. Subject is receiving or expected to receive prohibited concomitant medication(s) in the 4 weeks prior to the first dose of study drug and through follow-up visit.
  24. Any other condition which in the opinion of the investigator would make the subject unsuitable for inclusion in the study.
  25. Subject with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease), or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  26. Subject with a history of thromboembolic events, including deep vein thromboses (DVT), pulmonary embolism (PE), and those with known inherited conditions that predispose to hypercoagulability.

Study Exclusion Criteria for Parts 2 and 3

  1. Subject with any clinically significant condition at the end of 8-week Induction treatment from Part 1 Induction phase, and Part 2 Maintenance Phase that in the opinion of investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis.
  2. Subject who, in the opinion of the investigator or sponsor, is unlikely to be cooperative or able to comply with study procedures, or any other condition which in the opinion of the investigator would make the subject unsuitable for inclusion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
368 participants (estimated)

Study arms

  • Experimental
    Part 1 Active Experimental: SHR0302 Dose#1

    SHR0302 Oral tablets taken once daily (QD) for 8 weeks SHR0302 Oral tablets taken once daily (QD)

    Drug: SHR0302

  • Placebo comparator
    Part 1 Placebo Comparator: Placebo

    Placebo Oral tablets taken once daily (QD) for 8 weeks

    Drug: Placebo

  • Experimental
    Part 2 Active Experimental: SHR0302 Dose#2

    SHR0302 Oral tablets taken once daily (QD) for 44 weeks

    Drug: SHR0302

  • Placebo comparator
    Part 2 Placebo Comparator: Placebo

    Placebo Comparator: Maintenance Treatment Placebo Comparator: Placebo

    Drug: Placebo

  • Experimental
    Part 3 Active Experimental: SHR0302 Dose#2

    SHR0302 Oral tablets taken once daily (QD) for 26 weeks

    Drug: SHR0302

Interventions

  • Oral tablets taken once daily (QD)

  • DrugPlacebo

    Oral tablets taken once daily (QD)

06

What researchers measure

Primary outcomes

  1. Clinical remission at week 8 (Part 1)

    The percentage of subjects in clinical remission at week 8.

    Time frame: 8 weeks

  2. Clinical remission at week 52 (Part 2)

    The percentage of subjects in clinical remission at week 52.

    Time frame: 52 weeks

Secondary outcomes

  1. Endoscopic remission at week 8 (Part 1)

    The percentage of subjects with endoscopic remission at week 8.

    Time frame: 8 weeks

  2. Clinical response at week 8 (Part 1)

    The percentage of subjects with clinical response at week 8.

    Time frame: 8 weeks

  3. Change from baseline in partial Mayo score at week 2, 4, and 8 (Part 1)

    Change from baseline in partial Mayo score at week 2, 4, and 8.

    Time frame: 8 weeks

  4. Change in total Mayo score and 9-point modified Mayo score at week 8 (Part 1)

    Change in total Mayo score and 9-point modified Mayo score at week 8.

    Time frame: 8 weeks

  5. Subjects with endoscopic remission (Part 2)

    The percentage of subjects with endoscopic remission at week 52.

    Time frame: 52 weeks

  6. Subjects with clinical response at week 52 (Part 2)

    The percentage of subjects with clinical response at week 52.

    Time frame: 52 weeks

  7. Change from baseline in partial Mayo score at week 12, 16, 24, 32, 40, and 52 (Part 2)

    Change from baseline in partial Mayo score at week 12, 16, 24, 32, 40, and 52.

    Time frame: 52 weeks

  8. Change in total Mayo score and 9-point modified Mayo score at week 52 (Part 2)

    Change in total Mayo score and 9-point modified Mayo score at week 52.

    Time frame: 52 weeks

  9. Subjects in corticosteroid-free remission at week 52 (Part 2)

    Percentage of subjects in corticosteroid-free remission at week 52.

    Time frame: 52 weeks

  10. Subjects who maintain clinical remission at week 52 (Part 2)

    Percentage of subjects who maintain clinical remission at week 52

    Time frame: 52 weeks

  11. Subjects in clinical remission per partial Mayo score at week E26 (Part 3)

    The percentage of subjects in clinical remission per partial Mayo score at week E26.

    Time frame: 26 weeks (extension)

  12. Subjects in corticosteroid-free remission per Partial Mayo score at week E26 (Part 3)

    The percentage of subjects in corticosteroid-free remission per Partial Mayo score at week E26.

    Time frame: 26 weeks (extension)

  13. Change from baseline in Partial Mayo score at week E2, E12, and E26 (Part 3)

    Change from baseline in Partial Mayo score at week E2, E12, and E26.

    Time frame: 26 weeks (extension)

07

Study locations

48 of 113 sites recruiting
  • Digestive Health Specialists
    Dothan, Alabama 36301, United States
    Completed

    Not enrolling at this site — choose another above.

  • Om Research LLC
    Lancaster, California 93534, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Yale University
    New Haven, Connecticut 06510, United States
    Terminated

    Not enrolling at this site — choose another above.

  • IHS Health
    Kissimmee, Florida 34741, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dade Research Center
    Miami, Florida 33126, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Gastro Florida
    Pinellas Park, Florida 33781, United States
    Completed

    Not enrolling at this site — choose another above.

  • One Health Research Clinic Atlanta, LLC
    Norcross, Georgia 30039, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • John Hopkins University
    Columbia, Maryland 21045, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Michigan Medical
    Ann Arbor, Michigan 48109, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Research Institute of Michigan
    Chesterfield, Michigan 48047, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • NY Scientific
    Brooklyn, New York 11235, United States
    Terminated

    Not enrolling at this site — choose another above.

  • DiGiovanna Institute for Medical Education & Research
    North Massapequa, New York 11758, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Charlotte Gastroenterology & Hepatology P.L.L.C
    Charlotte, North Carolina 28207, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • DDSI
    Oklahoma City, Oklahoma 73112, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Central Sooner Research
    Oklahoma City, Oklahoma 73118, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Vanderbilt University Medical Center
    Nashville, Tennessee 37204, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Omni Clinical Research
    Houston, Texas 77034, United States
    Terminated

    Not enrolling at this site — choose another above.

  • UTMB Health
    League City, Texas 77573, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Utah
    Salt Lake City, Utah 84132, United States
    Terminated

    Not enrolling at this site — choose another above.

  • McGuire Research Institute
    Richmond, Virginia 23249, United States
    Terminated

    Not enrolling at this site — choose another above.

  • IACT Health
    Suffolk, Virginia 23435, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Advocate Aurora Health - Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
    Terminated

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui, China
    Recruiting
    • Qizhi Wang · Contact
    • Qizhi Wang · Principal investigator
  • Anhui Provincial Hospital
    Hefei, Anhui, China
    Recruiting
    • Li Xie · Contact
    • Li Xie · Principal investigator
  • Beijing Military Area General Hospital/Seventh Medical Center of PLA General Hospital
    Beijing, Beijing, China
    Recruiting
    • Jianqiu Sheng · Contact
    • Jianqiu Sheng · Principal investigator
  • Peking University First Hospital
    Beijing, Beijing, China
    Terminated

    Not enrolling at this site — choose another above.

  • Peking University Third Hospital
    Beijing, Beijing, China
    Recruiting
    • Shigang Ding · Contact
    • Shigang Ding · Principal investigator
  • Tsinghua University Changgung Hospital
    Beijing, Beijing, China
    Not yet recruiting
    • Bo Jiang · Contact
    • Bo Jiang · Principal investigator
  • Army Medical Center of PLA
    Chongqing, Chongqing, China
    Recruiting
    • Dongfeng Chen · Contact
    • Dongfeng Chen · Principal investigator
  • Chongqing People's Hospital
    Chongqing, Chongqing, China
    Recruiting
    • Hong Guo · Contact
    • Hong Guo · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
    Recruiting
    • Bingqiang Zhang · Contact
    • Bingqiang Zhang · Principal investigator
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
    Recruiting
    • Chengdang Wang · Contact
    • Chengdang Wang · Principal investigator
  • The First Affiliated Hospitial of Xiamen University
    Xiamen, Fujian, China
    Recruiting
    • Jianwei Zheng · Contact
    • Jianwei Zheng · Principal investigator
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Yongjia Zhou · Contact
    • Yongjian Zhou · Principal investigator
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Baili Chen · Contact
    • Baili Chen · Principal investigator
  • The Sixth Affiliated Hospital of Sun Yat-Sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Xiang Gao · Contact
    • Xiang Gao · Principal investigator
  • Third Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • Mingsong Li · Contact
    • Mingsong Li · Principal investigator
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong, China
    Recruiting
    • Bing Zou · Contact
    • Bing Zou · Principal investigator
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Recruiting
    • Xiaoping Lv · Contact
    • Xiaoping Lv · Principal investigator
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Xiaolan Zhang · Contact
    • Xiaolan Zhang · Principal investigator
  • The First Affiliated Hospital of Henan University of Science and Technoloy
    Luoyang, Henan, China
    Recruiting
    • Yingjian Zhang · Contact
    • Yingjian Zhang · Principal investigator
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Xiuling Li · Contact
    • Xiuling Li · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Recruiting
    • Bingrong Liu · Contact
    • Bingrong Liu · Principal investigator
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Hena, China
    Recruiting
    • Baisui Feng · Contact
    • Feng Feng · Principal investigator
  • Jingzhou First People's Hospital
    Jingzhou, Hubei, China
    Recruiting
    • Qing Zhang · Contact
    • Qing Zhang · Principal investigator
  • Affiliated Taihe Hospital of Hubei University of Medicine
    Shiyan, Hubei, China
    Recruiting
    • Shengbao Li · Principal investigator
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
    Not yet recruiting
    • Ping An · Contact
    • Ping An · Principal investigator
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
    • Xuehong Wang · Contact
    • Xuehong Wang · Principal investigator
  • Xiangya Hospital Central South University
    Changsha, Hunan, China
    Recruiting
    • Xiaomei Zhang · Contact
    • Xiaomei Zhang · Principal investigator
  • Zhuzhou Central Hospital
    Zhuzhou, Hunan, China
    Recruiting
    • Hongbing Zhou · Contact
    • Hongbing Zhou · Principal investigator
  • Baotou Central Hospital
    Baotou, Inner Mongolia, China
    Recruiting
    • Ling Zhang · Contact
    • Ling Zhang · Principal investigator
  • Huai'an First People's Hospital
    Huai'an, Jiangsu, China
    Recruiting
    • Weijie Dai · Contact
    • Weijie Dai · Principal investigator
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
    Not yet recruiting
    • Hongjie Zhang · Contact
    • Hongjie Zhang · Principal investigator
  • Nanjing First Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Zhenyu Zhang · Contact
    • Zhenyu Zhang · Principal investigator
  • Nanjing General Hospital of Nanjing Military Command
    Nanjing, Jiangsu, China
    Recruiting
    • Fangyu Wang · Contact
    • Fangyu Wang · Principal investigator
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
    Recruiting
    • Hong Chen · Contact
    • Hong Chen · Principal investigator
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
    • Weichang Chen · Contact
    • Weichang Chen · Principal investigator
  • Subei People's Hospital of Jiangsu province
    Yangzhou, Jiangsu, China
    Recruiting
    • Zhen Zhu · Contact
    • Zhen Zhu · Principal investigator
  • Shengjing Hospital Of China Medical University
    Shenyang, Liaoning, China
    Recruiting
    • Changqing Zheng · Contact
    • Changqing Zheng · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Terminated

    Not enrolling at this site — choose another above.

  • Binzhou Medical University Hospital
    Binzhou, Shandong, China
    Recruiting
    • Chengxia Liu · Principal investigator
  • Liaocheng People's Hospital
    Liaocheng, Shandong, China
    Recruiting
    • Peng Yan · Contact
    • Peng Yan · Principal investigator
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai, China
    Recruiting
    • Liang Zhong · Contact
    • Liang Zhong · Principal investigator
  • Longhua Hospital Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai, China
    Terminated

    Not enrolling at this site — choose another above.

  • Renji Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
    Terminated

    Not enrolling at this site — choose another above.

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
    Recruiting
    • Jie Zhong · Contact
    • Jie Zhong · Principal investigator
  • Shanghai Changhai Hospital
    Shanghai, Shanghai, China
    Recruiting
    • Yiqi Du · Contact
    • Yiqi Du · Principal investigator
  • Shanghai East Hospital
    Shanghai, Shanghai, China
    Terminated

    Not enrolling at this site — choose another above.

  • Shanghai General Hospital
    Shanghai, Shanghai, China
    Terminated

    Not enrolling at this site — choose another above.

  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai, China
    Terminated

    Not enrolling at this site — choose another above.

  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
    Recruiting
    • Xizhong Shen · Contact
    • Xizhong Shen · Principal investigator
  • Shanxi Provincial People's Hospital
    Shanxi, Shanxi, China
    Terminated

    Not enrolling at this site — choose another above.

  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
    Recruiting
    • Lijuan Huo · Contact
    • Lijuan Huo · Principal investigator
  • West China Hospital Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Yan Zhang · Contact
    • Yan Zhang · Principal investigator
  • Tianjin medical University General Hospital
    Tianjin, Tianjin, China
    Recruiting
    • Bangmao Wang · Contact
    • Bangmao Wang · Principal investigator
  • Tianjin Union Medical Center
    Tianjin, Tianjin, China
    Recruiting
    • Yandi Liu · Contact
    • Yandi Liu · Principal investigator
  • The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Yihong Fan · Contact
    • Yihong Fan · Principal investigator
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Yan Chen · Contact
    • Yan Chen · Principal investigator
  • Jinhua Municipal Central Hospical
    Jinhua, Zhejiang, China
    Recruiting
    • Jin Ding · Contact
    • Jin Ding · Principal investigator
  • Ningbo First Hospital
    Ningbo, Zhejiang, China
    Recruiting
    • Xiaoyun Ding · Contact
    • Xiaoyun Ding · Principal investigator
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
    Recruiting
    • Xiangrong Chen · Contact
    • Xiangrong Chen · Principal investigator
  • Curatio, Jsc
    Tbilisi, Georgia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
    Tbilisi, Georgia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • LTD Central University Clinic After Academic N. Kipshidze
    Tbilisi, Georgia
    Completed

    Not enrolling at this site — choose another above.

  • LTD The First Medical Center
    Tbilisi, Georgia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CLINSANTE Clinical Research Centre Ewa Galczak-Nowak, Malgorzata Trzaska
    Bydgoszcz, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • MZ BADANIA Slowik Zymla General Partnership
    Knurow, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • "Landa" Specialist Doctor's Offices
    Krakow, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • PLEJADY Medical Centre
    Krakow, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AMED Medical Centre Branch in Lodz
    Lodz, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Oswiecim Clinical Trial Centre
    Oswiecim, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Private Healthcare Institution Specialist Clinics Termedica
    Poznan, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Dariusz Kleczkowski Specialist Medical Practice
    Sopot, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Torun Gastrology Centre "Gastromed"
    Torun, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MDM Healthcare Centre
    Warsaw, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • WIP Warsaw IBD Point
    Warsaw, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Medical Centre Oporow
    Wroclaw, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ETG Zamosc
    Zamosc, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Communal Nonprofit Enterprise "Cherkasy Regional Hospital of Cherkasy Oblast Council"
    Cherkasy, Ukraine
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 113 sites across 5 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Oct 2024, 35 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 35 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Jan 6, 2022
StartActual
Nov 5, 2021
Primary completionEst.
Oct 31, 2024
CompletionEst.
Mar 31, 2025
Last update
Sep 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05181137
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Nov 5, 2021
Primary completion
Oct 31, 2024 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Sep 5, 2023

Study contacts

Minna Sun
Contact
minna.sun@reistonebio.com
+86 18611785877
Lingyu Guo
Contact
lingyu.guo@reistonebio.com
+86 13311061570
Xiang Chen
study director · Reistone Pharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion